Moderna Cancer Vaccine: mRNA Melanoma Shot Succeeds in First Phase 3 Trial

Published: 19 Aug 2026, 10:28 pm IST

Moderna and Merck announced on 19 August 2026 that their personalised mRNA cancer therapy, intismeran autogene, succeeded in its first Phase 3 trial. In patients whose melanoma had been surgically removed, adding intismeran to Merck’s immunotherapy Keytruda kept cancer from returning significantly longer than Keytruda alone.

This is the first time any individualised neoantigen therapy — and any mRNA-based cancer therapy — has succeeded in a Phase 3 trial. Moderna’s stock more than doubled on the news.

But the announcement is a topline result, not a full dataset. The companies have not released hazard ratios, survival curves or the size of the benefit. Whether the treatment helps people live longer is still unknown. And the therapy is not approved or available anywhere in the world.

Here is what was actually announced, what it means, and what still has to be proven.

What Merck and Moderna announced

The trial is called INTerpath-001. It tested whether adding intismeran autogene to Keytruda after melanoma surgery works better than Keytruda alone.

The result: the trial met its primary endpoint of recurrence-free survival (RFS) and a key secondary endpoint of distant metastasis-free survival (DMFS). Both improvements were described as statistically significant and clinically meaningful compared with Keytruda alone.

In plain terms:

Recurrence-free survival measures how long patients go without their cancer coming back anywhere, or dying from any cause.
Distant metastasis-free survival measures how long patients go without the cancer spreading to distant organs, or dying.

The second endpoint matters more than it sounds. Melanoma that returns as a small local nodule is often manageable. Melanoma that spreads to the lungs, liver or brain is a different disease with far worse outcomes. Showing a delay in distant spread — not just any recurrence — is a meaningfully harder result to achieve.

Merck also reported no new safety signals. Side effects were consistent with what has been seen previously for the combination.

The result came at a pre-specified interim analysis. Under the trial protocol, the study continues in order to evaluate remaining secondary endpoints, including overall survival.

Professor Georgina Long, the study’s principal investigator and medical director of Melanoma Institute Australia, said the combination has the potential to <cite index=”45-1″>”establish a new treatment paradigm in the adjuvant melanoma setting.”</cite>

Data will be presented at an international medical meeting and shared with regulators. No date has been announced for either.

What intismeran autogene actually is

This is where most coverage gets loose, and where the misunderstanding matters.

Intismeran autogene is not a vaccine in the way most people use that word. It does not prevent cancer. You cannot get it to avoid getting melanoma. It is a therapeutic treatment given to people who already have a cancer diagnosis.

The technical name is an individualised neoantigen therapy (INT). It is also known by its development codes mRNA-4157 and V940.

How it is made

Each dose is manufactured for one specific patient. The process works roughly like this:

A sample of the patient’s tumour is taken, usually from the surgery that removed it.
The tumour is genetically sequenced and compared against the patient’s healthy tissue.
Mutations unique to that tumour are identified. These mutations produce abnormal proteins called neoantigens — flags that exist on the cancer cells and nowhere else in the body.
An algorithm selects up to 34 of these neoantigens, prioritising the ones most likely to provoke a strong immune response.
A synthetic mRNA is built encoding those specific neoantigens, and manufactured into a therapy for that patient alone.

When injected, the body’s cells read that mRNA and produce the neoantigen proteins. The immune system sees them, learns to recognise them, and generates T cells trained to hunt cells carrying those exact flags — which, in principle, is only the cancer.

Why it is paired with Keytruda

Keytruda (pembrolizumab) is a checkpoint inhibitor. Tumours often suppress T cells using the PD-1 pathway; Keytruda blocks that suppression.

The logic of the combination is a division of labour. Intismeran tells the immune system what to attack. Keytruda stops the tumour from switching off the attack. Neither is expected to work as well alone.

This is also why the trial design is fair: everyone in the study received Keytruda, which is already an approved standard of care in this setting. The question was purely whether adding intismeran on top delivers additional benefit.

Inside the trial: INTerpath-001

The trial details matter for judging how strong this result is.

Element	Detail
Trial ID	NCT05933577
Design	Randomised, double-blind, placebo- and active-comparator-controlled, global Phase 3
Patients enrolled	1,137
Population	Completely resected stage IIB, IIC, III or IV cutaneous melanoma, no prior systemic therapy
Randomisation	2:1 (intismeran + Keytruda vs Keytruda alone)
Intismeran dosing	1 mg every three weeks, up to nine doses
Keytruda dosing	400 mg every six weeks, up to nine cycles (~one year)
Total treatment	Up to approximately 56 weeks
Primary endpoint	Recurrence-free survival
Key secondary endpoints	DMFS, overall survival, safety, tolerability, quality of life

Three design features are worth highlighting.

It is double-blind and placebo-controlled. Neither patients nor investigators knew who received intismeran. This removes a major source of bias that weaker trial designs suffer from.

The comparator is real. Keytruda alone is the actual standard of care for resected stage IIB, IIC and III melanoma. Beating it is a genuine bar, not a straw man. Many trials that look impressive are compared against placebo or outdated treatment.

It is limited to cutaneous melanoma. The trial enrolled patients with melanoma of the skin. Results cannot automatically be assumed to apply to other melanoma subtypes.

What this result does not tell us

This section matters more than the headline, and most coverage has skipped past it.

The size of the benefit is unknown

Merck and Moderna reported that the endpoints were met. They did not release hazard ratios, confidence intervals, median recurrence-free survival, or the absolute difference between the two groups.

“Statistically significant” means the result is unlikely to be chance. It says nothing about magnitude. A treatment can be statistically significant and clinically modest. The companies also used the phrase “clinically meaningful,” which is an assessment, not a number.

Until the curves are presented, nobody outside the companies and the data monitoring committee knows how large the effect is.

Overall survival is unresolved

This is the central open question.

Recurrence-free survival measures delay of recurrence. Overall survival measures whether people live longer. They are not the same thing, and in melanoma specifically they can diverge.

The reason is that modern melanoma treatment is genuinely good. A patient whose cancer returns today usually has effective options available — including Keytruda and other immunotherapies. So patients in the control group whose cancer comes back may still be treated successfully and live a long time. That can compress any survival difference between the two groups, even when the recurrence difference is real.

Because the trial stopped at its first interim analysis for the primary endpoint, the overall survival question remains open and may take years to answer.

This is not a criticism of the result. Delaying recurrence and preventing distant spread has real value on its own — recurrence means more treatment, more scans, more anxiety, and worse odds. But anyone claiming this therapy has been shown to help people live longer is going beyond the evidence.

It is a single trial in a single cancer

INTerpath-001 covers resected cutaneous melanoma. Trials in lung, bladder and kidney cancer are ongoing but have not read out. Melanoma is unusually responsive to immunotherapy; it has historically been the cancer where immune-based treatments work first and best. Success here does not guarantee success elsewhere.

The Phase 2 data behind it

This Phase 3 result did not come out of nowhere. It builds on the Phase 2b KEYNOTE-942 / mRNA-4157-P201 trial, a much smaller study whose five-year follow-up was presented at the 2026 ASCO Annual Meeting.

In that study, the combination showed:

A 49% reduction in the risk of recurrence or death (HR = 0.51; 95% CI, 0.294–0.887)
A 59% reduction in the risk of distant metastasis or death (HR = 0.411; 95% CI, 0.200–0.843)

Those are striking numbers, and they are the main reason expectations for the Phase 3 were high.

But read the confidence intervals. They are wide — the upper bound on the recurrence figure reaches 0.887, close to no effect. That width reflects the small sample: the Phase 2b analysis involved roughly 157 patients. Small trials produce imprecise estimates, and effect sizes commonly shrink when tested in larger populations.

This is exactly why Phase 3 trials exist, and it is why the Phase 3 effect size — when released — may well be smaller than the Phase 2b figures. That would not make the result a failure. It would make it normal.

Why scientists are calling this a landmark

Strip away the stock move and the significance is real.

Personalised cancer vaccines have been an aspiration for over a decade. The concept — sequence a tumour, find its unique mutations, train the immune system against them — has been theoretically compelling and practically frustrating. Early trials showed immune responses. Turning immune responses into clinical benefit proved much harder.

This is the first randomised Phase 3 trial to show that the approach delivers a clinical benefit over an established standard of care.

It is also a validation of mRNA beyond infectious disease. mRNA’s public reputation was built on COVID-19 vaccines. The theoretical promise was always broader: because mRNA is essentially software written in biological code, the same manufacturing platform can produce a completely different product by changing the sequence. A personalised cancer therapy — where every single dose is a different sequence — is close to the hardest possible test of that idea. It appears to have worked.

It suggests a general principle may hold. If training T cells against tumour-specific mutations works in melanoma, the same logic could apply anywhere a tumour carries enough distinctive mutations. That is the bet the ongoing trials in lung, bladder and kidney cancer are testing.

The market reaction, and why it was so extreme

Moderna’s stock moved violently on the announcement.

Reported figures varied through the day: shares rose roughly 60% in early premarket trading, climbed above 100% in later premarket, and Forbes reported the stock up about 125.9% to around $142 by late morning on 19 August — pacing what would be the company’s best-ever trading session. Merck rose far more modestly, in the mid-single digits.

These figures are live and will be stale quickly. Check a current quote before relying on any number here.

The asymmetry between the two companies explains most of the story.

For Merck, this is an addition. Keytruda is already one of the highest-selling medicines in the world. A successful combination extends its franchise, but Merck’s business does not hinge on it.

For Moderna, this was close to existential. The company’s revenue collapsed from its COVID-19 peak. Oncology represents its most credible path to a second act. Before the readout, Leerink Partners analyst Mani Foroohar had described the Phase 3 data as a make-or-break event for the stock.

Two technical factors amplified the move. Wall Street was overwhelmingly cautious going in — the large majority of covering analysts held “hold” or worse ratings, and consensus price targets sat far below where the stock opened. And short interest was heavy, at roughly 13% of the available float, meaning a sharp rise forces short sellers to buy back shares, pushing the price higher still.

A necessary caution on the stock story

A share price is a statement about expectations, not about medicine. The move reflects investors pricing in a scenario where intismeran works across multiple cancers, wins approval, and reaches a large market. None of that is established.

Specifically, the market is currently pricing a therapy for which the effect size is undisclosed, the survival benefit is unproven, no regulatory filing has been submitted, no approval exists in any country, and no price has been set.

Nothing in this article is investment advice. Single-catalyst biotech moves of this magnitude are frequently followed by significant volatility in both directions once full data arrives.

The regulatory path ahead

Merck and Moderna have said they will engage with regulators on filing submissions. They have not said when, or in which markets first.

Some relevant history: Moderna sought accelerated approval for this therapy in 2024 on the strength of the Phase 2b data and was turned down by the FDA. That rejection is part of why a full Phase 3 was necessary — and why this result carries weight the earlier data did not.

Realistic expectations on timing:

Full data presentation at a major oncology meeting, likely the next available international forum
Regulatory submissions after that, in the US, EU and other markets
Review periods typically measured in months, sometimes accelerated for oncology
Country-by-country approval, meaning availability will not arrive everywhere at once

For a therapy of this type, approval in one market says little about timing in another. India, in particular, would require a separate regulatory process, and personalised therapies raise additional questions around sample logistics and manufacturing that do not apply to conventional drugs.

The manufacturing problem nobody has solved yet

This is the least-discussed obstacle and possibly the most important.

Conventional medicines are manufactured in batches. One production run makes thousands of identical doses. Intismeran cannot work that way. Every patient requires a separate manufacturing run, built from their own tumour sequence.

That creates a chain of practical requirements:

Tumour tissue must be collected and shipped under conditions that preserve it for sequencing.

Sequencing and neoantigen selection must be fast. Melanoma recurrence after surgery most often happens within the first two years, so a delay of months between surgery and first dose erodes the benefit.

Manufacturing capacity must scale with patient numbers, not with volume of a single product. Doubling the number of patients means doubling the number of production runs.

Quality control applies to every individual batch, because every batch is a different product.

Cost is unknown but unlikely to be low. No price has been announced. Sequencing, bespoke manufacturing and cold-chain logistics for a one-patient product are structurally expensive.

None of this makes the therapy unworkable — the trial itself successfully manufactured and delivered doses to hundreds of patients across multiple countries, which is itself a meaningful proof of feasibility. But scaling from a trial to routine clinical use is a different problem, and it will shape who actually gets access.

For health systems in lower- and middle-income countries, this is the question that will determine whether the science translates into available treatment.

What this means for patients right now

Clear, practical guidance, because this is where inaccurate reporting causes real harm.

The therapy is not available. It is investigational. It is not approved in the United States, the European Union, India, or anywhere else.

Nobody should change their current treatment. Patients undergoing melanoma treatment should continue exactly as their oncologist has directed. A press release about a trial is not a reason to alter, pause or delay an existing plan.

This does not prevent cancer. It is given after a cancer diagnosis and after surgery.

It applies to a specific group. The trial enrolled people with completely resected stage IIB–IV cutaneous melanoma who had not received prior systemic therapy. It says nothing directly about advanced melanoma that cannot be removed surgically, about other skin cancers, or about other cancer types.

Clinical trials are the only current access route. Merck and Moderna are running nine Phase 2 and Phase 3 trials in the INTerpath programme across melanoma, non-small cell lung cancer, bladder cancer and renal cell carcinoma, plus a Phase 1 study in pancreatic, gastric and lung settings. Anyone interested should raise it with their treating oncologist, who can assess eligibility. ClinicalTrials.gov lists active studies and locations.

The most useful thing most people can do about melanoma has nothing to do with this news. Melanoma caught early is often curable by surgery alone. Sun protection and getting changing moles checked remain far more consequential for the general population than any experimental therapy.

Beyond melanoma: what comes next

The INTerpath programme currently comprises nine Phase 2 and Phase 3 trials across multiple tumour types:

Melanoma — including this adjuvant trial and a Phase 2 study in first-line metastatic disease
Non-small cell lung cancer — two Phase 3 studies in the adjuvant setting, plus a Phase 2 in metastatic squamous NSCLC
Bladder cancer — Phase 2 studies in muscle-invasive and non-muscle-invasive disease
Renal cell carcinoma — a randomised Phase 2 in the adjuvant setting

Separately, a Phase 1 study is exploring pancreatic ductal adenocarcinoma, perioperative gastric carcinoma and perioperative NSCLC.

Lung cancer is the readout that matters most. It is vastly more common than melanoma worldwide, including in India. If the approach works there, the population affected changes by an order of magnitude.

But melanoma was chosen first for a reason. It carries a high mutational burden — meaning lots of neoantigens to target — and it responds unusually well to immunotherapy. Cancers with fewer mutations offer the immune system fewer distinctive flags to recognise. Pancreatic cancer, for instance, is a far harder target for this approach. Success in melanoma is the beginning of the evidence, not the end of it.

An Indian perspective

A few points of context for readers in India.

Melanoma is comparatively uncommon in India relative to countries with large fair-skinned populations, where the disease is far more prevalent. The absolute number of patients directly addressed by this specific result is therefore smaller here than the global headlines suggest.

The trial studied cutaneous melanoma specifically — melanoma arising on sun-exposed skin. Melanoma subtypes and their biology vary across populations, and because neoantigen therapy depends on a tumour carrying enough distinctive mutations, subtype differences are relevant to whether findings translate. Readers should treat this as a question for a treating oncologist rather than a settled point.

The lung cancer trials are the ones to watch from an Indian standpoint. Lung cancer is among the most common cancers in India. If the platform works there, the relevance shifts dramatically.

Access will be the deciding factor. Even after approval elsewhere, a personalised therapy requiring tumour sequencing, bespoke manufacturing and cold-chain logistics faces a steeper path to availability in India than a conventional medicine. Regulatory approval, manufacturing partnerships and pricing will all need resolving.

What to watch next

Five concrete markers that will determine whether this holds up:

The full dataset. Hazard ratios, confidence intervals and Kaplan-Meier curves at the medical meeting presentation. This is when independent oncologists can finally judge the size of the benefit.

The safety detail. “No new safety signals” is reassuring but broad. The full data will show discontinuation rates, grade 3 and higher adverse events, and how many patients could not complete treatment.

Overall survival, eventually. The trial continues. This answer may take years and is the one that ultimately settles the therapy’s place in treatment.

Regulatory filings and decisions. Which agencies, which timeline, and whether any grant accelerated review.

Lung cancer readouts. The genuine test of whether this is a melanoma result or a platform.

The honest summary

A personalised mRNA cancer therapy has, for the first time, beaten a strong standard of care in a properly designed Phase 3 trial. That is a genuine scientific milestone, and the people who spent a decade pursuing this idea have earned the moment.

It is also a topline press release with no effect sizes, no survival data, no regulatory filing and no approval. The therapy is not available to anyone outside a trial, and the manufacturing and cost questions that will decide who ever receives it remain entirely unaddressed.

Both of those things are true simultaneously. Coverage that reports only the first is doing readers a disservice; coverage that reports only the second is missing something real.

Key Takeaways

Moderna and Merck announced on 19 August 2026 that intismeran autogene plus Keytruda met its primary endpoint (recurrence-free survival) and a key secondary endpoint (distant metastasis-free survival) in the Phase 3 INTerpath-001 trial.
This is the first positive Phase 3 result for any individualised neoantigen therapy and any mRNA-based cancer therapy.
The trial enrolled 1,137 patients with completely resected stage IIB–IV cutaneous melanoma, randomised 2:1.
No hazard ratios, confidence intervals or effect sizes have been released. Overall survival remains unresolved and the trial continues.
No new safety signals were reported.
Supporting Phase 2b data (KEYNOTE-942) showed a 49% reduction in recurrence or death and a 59% reduction in distant metastasis or death at five years, but in only about 157 patients with wide confidence intervals.
Moderna’s stock more than doubled; Merck rose modestly. The move reflects expectations, not established outcomes.
The therapy is investigational and not approved or available in any country.
Trials are ongoing in lung, bladder and kidney cancer. Lung cancer is the readout with the widest global relevance.

FAQs

What is Moderna cancer vaccine called?
- Intismeran autogene, also known by its development codes mRNA-4157 and V940. It is described technically as an individualised neoantigen therapy (INT), jointly developed by Moderna and Merck.
Does the Moderna cancer vaccine prevent cancer?
- No. It is a therapeutic treatment given to people already diagnosed with cancer, after surgical removal of the tumour. It is not a preventive vaccine and cannot be taken to avoid developing cancer.
Is the Moderna cancer vaccine approved?
- No. It is investigational and is not approved in the United States, the European Union, India or anywhere else. Merck and Moderna have said they will engage with regulators on filing submissions, but no filing or approval timeline has been announced.
What did the Phase 3 trial show?
- The INTerpath-001 trial met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival, with results described as statistically significant and clinically meaningful compared with Keytruda alone. Specific effect sizes have not been released.
How does the mRNA cancer vaccine work?
- A patient’s tumour is sequenced to identify mutations unique to their cancer. Up to 34 of the resulting neoantigens are selected and encoded into a synthetic mRNA made specifically for that patient. Once injected, the body produces those neoantigens, training T cells to recognise and attack cells carrying them.
Why is it given with Keytruda?
- Keytruda is a checkpoint inhibitor that stops tumours from suppressing T cells. Intismeran directs the immune system to specific targets; Keytruda helps keep that immune response active. The combination is designed to do both jobs together.